BOSTON SCIENTIFIC CORP

Boston Scientific’s analyst sentiment shifts as TD Cowen cuts its target to $56.00 while the company trims jobs, sparking a mixed outlook on future growth.

Boston Scientific’s valuation tightens as analysts trim targets and the firm cuts jobs, raising concerns about its growth prospects and future innovation in medical devices.

Boston Scientific’s stock rebounds to $44.65 amid market volatility, showcasing its robust portfolio of minimally invasive devices and promising growth prospects for investors.

Boston Scientific tops Q1 earnings, beating EPS estimates but cuts 2026 sales guidance amid supply‑chain uncertainty—stock surges yet faces legal deadlines.

Boston Scientific shares hit a $61.86 close as investors face a May 4, 2026 litigation deadline—earnings guidance shows upside while institutional selling raises caution.

Boston Scientific’s CHAMPION‑AF trial hits all endpoints, boosting its $93B market cap. See how institutional trades, SEC filings, and device launches shape its growth.

Boston Scientific’s WATCHMAN FLX and EKOS trials confirm breakthrough safety, boosting market confidence amid active trading and a pending class‑action lawsuit.

Boston Scientific (BSX) sees bullish analyst coverage, institutional buys, and steady but declining prices—insightful for investors targeting health‑care equipment growth.

Boston Scientific Corp. has reported a strong third-quarter performance, exceeding analyst expectations and boosting its annual profit forecast, driven by surging demand for its heart-device portfolio.

Boston Scientific Corp has reported a 22.8% increase in net sales to $5.061 billion, exceeding expectations and setting a new benchmark for the company’s financial performance.